Abstract
Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/ organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
Keywords: Systemic Sclerosis, fibrosis, biologic therapies, Rituximab, Tocilizumab.
Current Medicinal Chemistry
Title:Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Volume: 22 Issue: 16
Author(s): Theodoros Dimitroulas, Dimitrios Daoussis, Alexandros Garyfallos, Petros P. Sfikakis and George D. Kitas
Affiliation:
Keywords: Systemic Sclerosis, fibrosis, biologic therapies, Rituximab, Tocilizumab.
Abstract: Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/ organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
Export Options
About this article
Cite this article as:
Dimitroulas Theodoros, Daoussis Dimitrios, Garyfallos Alexandros, P. Sfikakis Petros and D. Kitas George, Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150209161224
DOI https://dx.doi.org/10.2174/0929867322666150209161224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in
Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Epigenetic Multiple Modulators
Current Topics in Medicinal Chemistry Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews Development and Validation of HPLC Method to Determine Colchicine in Pharmaceutical Formulations and its Application for Analysis of Solid Lipid Nanoparticles
Current Pharmaceutical Analysis Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Knock-Out Mice in Osteoarthritis Research
Current Rheumatology Reviews Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Forceps: Still an Option?
Current Women`s Health Reviews Polysaccharide Production in Pilot Scale Bioreactor Cultivations of Neisseria meningitidis Serogroup C
Current Biochemical Engineering (Discontinued) Primary Sjögren’s Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Pulmonary Involvement in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy Behcets Syndrome: Literature Review
Current Rheumatology Reviews Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report
Infectious Disorders - Drug Targets Modulation of the Rho/ROCK Pathway in Heart and Lung after Thorax Irradiation Reveals Targets to Improve Normal Tissue Toxicity
Current Drug Targets